I am happy to announce that Lieping Chen, MD, PhD has accepted a position as Director of Cancer Immunology at Yale Cancer Center. Lieping is internationally known for his leadership in cancer immunobiology and his appointment at Yale Cancer Center will ensure Yale continues as a leader in cancer immunobiology, not only in our basic science laboratories but in our clinics as well. His commitment to translating basic discoveries from the lab and developing new strategies to treat cancer using novel biologics in clinical trials will serve as a model for our translational research initiatives. Lieping joins us on September 1 from Johns Hopkins University School of Medicine.
Magazine Honors Best Docs
Congratulations to the 28 Yale Cancer Center physicians who were recognized on the 2010
Magazine Best Doctors list.
The following members of Yale Cancer Center were recognized in the 2010 publication:
Allen Bale John Persing
Jean Bolognia Richard Peschel
John Colberg Joseph Piepmeier
Thomas Duffy Carrie Redlich
Richard Edelson Kenneth Roberts
Harris Foster Ronald Salem
Gary Friedlaender Clarence Sasaki
Silvio Inzucchi Peter Schwartz
John Kveton Richard Stahl
David Leffell Hugh Taylor
Walter Longo J. Grant Thomson
Thomas Lynch Robert Udelsman
Shirley McCarthy Jeffrey Weinreb
Pasquale Patrizio Lynn Wilson
will join the Yale School of Medicine development office as a Major Gifts Officer assigned to Yale Cancer Center on July 1. Peter was most recently responsible for the 50th Reunion gift campaigns at Yale University, and skillfully managed a host of reunion appeals, beginning with the 30th Reunion.
At Yale Cancer Center, Peter will manage a portfolio of major gift prospects and donors and work closely with YCC faculty and leadership to fundraise for the cancer center's highest priorities.
Jason Wilkin, PhD
, a fellow in the laboratory of Nita Maihle, PhD, was recently awarded a travel grant from the New York Academy of Sciences to present at their meeting, "Towards Personalized Cancer Medicine" in May in Barcelona, Spain. Dr. Wilken presented,
Trastuzumab Resistance--More than Just Proliferation?
, during the Hot Topics session of the meeting.
Two Yale Cancer Center members were awarded a 2010
Women's Health Research at Yale (WHRY)
award to support their ongoing research initiatives:
Dr. Alessandro Santin
intends to develop a novel mechanism for advancing chemotherapy for ovarian cancer by exploring the possibility of delivering a tumor-destroying chemotherapy using nanoparticles. Dr. Santin's work is co-funded by
Yale Cancer Center
Dr. Julie Ann Sosa
received a grant from
to develop an innovative approach to treat hypoparathyroidism, a condition in which the parathyroid glands malfunction, leading to low blood-calcium levels. Her research will induce human embryonic stem cells to develop into parathyroid cells that would secrete a parathyroid hormone and maintain normal calcium balance potentially leading to a cure for hypoparathyroidism.
Research in the News
Breast Milk Protein Linked to Poorer Breast Cancer Survival in Younger Women
In a study that sheds light on why breast cancer may be deadlier for premenopausal women, a research team led by John Wysolmerski, MD, a member of the Yale Cancer Center Signal Transduction Research Program, has linked breast cancer survival with levels of a transport protein that regulates milk production in mammary glands. The paper is published in the
Proceedings of the National Academy of Sciences.
Prenatal Exposure To BPA and DES May Increase Breast Cancer Risk
Exposure in the womb to chemicals like Bisphenol-A (BPA) and Diethylstilbestrol (DES) can increase an offspring's risk of breast cancer, researchers at Yale School of Medicine report in a study published in current issue of
Hormones and Cancer
, a journal of The Endocrine Society. The research was led by Yale Cancer Center Genetics and Genomics Research Program member Hugh Taylor, MD.
Department of Defense Peer Reviewed Cancer Research Program
Peer Reviewed Cancer Research Program
Translational New Investigator Award
is new for fiscal year 2010 and supports the development of translational research partnerships between two independent investigators. Within the partnership, one member must be a laboratory scientist and the other must be a clinician. This award is intended to support a mentoring partnership between a new investigator and an established research program.
The Peer Reviewed Cancer Research Program
is intended to promote the exploration of ideas that are still in the early stages of development yet have the potential to yield high-impact results and open new avenues of investigation. This mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements. Preliminary data are not required. However, research projects should include a well-formulated, testable hypothesis based on a strong scientific rationale.
A pre-application consisting of a two page narrative and biosketches is due July 14, 2010.
Promise Grants are intended support two or three principal investigators and an investigative team that brings together and integrates laboratory, clinical and/or public health disciplines to conduct several related projects, the results of which converge to answer critical questions. Relevant research applications may include components that focus on breast cancer biology; genetics; epidemiology; prevention; detection; risk assessment; biomarkers of risk, disease burden, and/or treatment response or resistance; novel therapeutics; lifestyle interventions with the potential to affect disease outcomes (e.g., incidence and/or mortality); and novel approaches that enhance understanding of the breast cancer disease process. Integrated programs of research projects addressing critical challenges in population disparities in breast cancer outcomes are of special interest and may receive funding priority.
For basic and clinical investigations relevant to the advancement of human health. Strong preference for creative and innovative approaches; risk-taking is encouraged.
For individuals who will hold a full-time appointment at the rank of assistant professor by November 1, 2010, but who will not have been in such an appointment form more than 3 years as of July 1, 2011.
To support the conduct of innovative and insightful medical research on the hematologic malignancies.
Funds are provided for clinical or basic science research that will lead to novel therapeutic approaches that could replace, or be used in combination with existing effective therapies for patients with leukemia, lymphoma, and related cancers. Such therapeutic approaches could include alternative or complementary medicine.
Smith Family Awards for Excellence in Biomedical Research
To support promising young scientists engaged in new and innovative research in all areas of basic biomedical science.
Investigators in physics, chemistry, and engineering with biomedical research projects are also encouraged to apply.
Clinical research is beyond the scope of this program.
Candidates must be full-time independent investigators who have completed not more than 2 years of a junior faculty appointment and will have been appointed to their first independent appointment between July 1, 2008 and December 1, 2010.
$300,000 to be used over a period of 3 years. ($300,000)